new option listings on July 28th » 08:3007/2807/28/21
ACHV, ADES, ALGS, ATCX, BBCP, BTTR, CDAK, CGA, CHMI, CRCT, CRTD, DRTT, EARN, EPS, ESXB, EZM, HMLP, ICL, IMXI, INTT, LIQT, MDWD, PSJ, RTPY, SGTX, SIC, USDP, VIRI, VYGG
New option listings for…
New option listings for July 28th include Achieve Life Sciences Inc (ACHV), Advanced Emissions (ADES), Market Vectors Africa (AFK), Aligos Therapeutics Inc (ALGS), Atlas Technical Consultants Inc (Class A Stock) (ATCX), Concrete Pumping Holdings Inc (BBCP), Better Choice Company Inc (BTTR), CBX (CBX), Codiak BioSciences Inc (CDAK), China Green (CGA), Cherry Hill Mortgage (CHMI), Cricut Inc (CRCT), Creatd Inc (CRTD), WisdomTree High Dividend Fund (DHS), Dirtt Environmental Solutions Ltd (DRTT), Ellington Residential (EARN), WisdomTree SmallCap Earnings Fund (EES), WisdomTree Earnings 500 Fund (EPS), Community Bankers Trust (ESXB), WisdomTree MidCap Earnings Fund (EZM), Hoegh LNG (HMLP), IBO (IBO), Israel Chemicals (ICL), iShares Evolved US Technology ETF (IETC), iShares Edge MSCI Intl Momentum Factor ETF (IMTM), International Money Express Inc (IMXI), inTest (INTT), WisdomTree International Quality Dividend Growth Fund (IQDG), iShares Russell Top 200 (IWL), iShares Russell Top 200 Value (IWX), iShares Dow Jones US (IYY), SPDR Russell 1000 Low Volatility ETF (LGLV), LiqTech (LIQT), MediWound (MDWD), Power Shares Food And Beverage (PBJ), PowerShares S&P 500 Buy Write Portfolio (PBP), PowerShares Dynamic Media Portfolio (PBS), PowerShares FTSE RAFI Developed Markets Ex US Sm Mid Portfolio (PDN), PowerShares Dynamic Building and Construction Portfolio (PKB), PowerShares S&P SmallCap Consumer Discretionary Portfolio (PSCD), Power Shares Dynamic Software Portfolio (PSJ), Powershares Dynamic Large Cap Growth Portfolio (PWB), Powershares Dynamic Large Cap Value Portfolio (PWV), PowerShares FTSE RAFI Developed Markets ex US Portfolio (PXF), PowerShares DWA Basic Materials Momentum Portfolio (PYZ), Reinvent Technology Partners Y (Class A Stock) (RTPY), Sigilon Therapeutics Inc (SGTX), Select Interior Concepts Inc (Class A Stock) (SIC), Presidio Property Trust Inc (Class A Stock) (SQFT), USD Partners (USDP), Virios Therapeutics Inc (VIRI), Vy Global Growth (Class A Stock) (VYGG), WisdomTree Cybersecurity Fund (WCBR), Innovative Technology ETF (XITK), and SPDR NYSE Technology (XNTK).
|Over a week ago|
Sigilon Therapeutics presents preclinical data on MPS, related diseases » 07:0507/2307/23/21
Sigilon Therapeutic reported results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2, and MPS-6. Three scientific abstracts were selected for presentation-including an oral presentation on MPS-1-during the 16th International Symposium on MPS and Related Diseases. "Despite approved therapies for MPS-1, including hematopoietic stem cell transplantation and enzyme replacement therapy, patients experience high treatment burden and long-term disease progression," said Rogerio Vivaldi M.D., M.B.A., President and CEO of Sigilon. "While still early in its development, we are highly encouraged by these results with SIG-005, which demonstrated active IDUA production for up to 6 months in vitro and in vivo, and a dose-response relationship with tissue GAG clearance in the MPS-1H mouse model." Sigilon recently filed a Clinical Trial Application in the United Kingdom for SIG-005 in MPS-1 and anticipates submitting an Investigational New Drug application and a CTA in the United States and Brazil, respectively. If approved, Sigilon expects to initiate a Phase 1/2 clinical trial of SIG-005 in patients with MPS-1 in the second half of 2021.
Sigilon Therapeutics price target lowered to $43 from $62 at Canaccord » 07:2507/1907/19/21
Canaccord analyst Michelle Gilson lowered the firm's price target on Sigilon Therapeutics to $43 from $62 and keeps a Buy rating on the shares. The analyst reduced the target following the clinical hold for its therapy in hemophilia A. The analyst said its platform remains intact and key opinion leaders continue to view the product as very promising.
Sigilon Therapeutics appoints Ajay Rai as SVP, head of business development » 07:0207/1907/19/21
Sigilon Therapeutics announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development. Most recently, Mr. Rai served as Vice President, Corporate Development, Strategy & Alliance Management at Frequency Therapeutics where he was responsible for evolving the company's overall business and corporate strategy and played an integral role in executing several financing rounds, including an Initial Public Offering.
Fly Intel: Pre-market Movers » 08:5607/0907/09/21
STMP, TBLT, NOVN, HGEN, GBX, LEVI, DCT, SGTX, XL
Check out this morning's…
Sigilon Therapeutics falls over 20% after FDA hold on SIG-001 phase 1/2 study » 08:1707/0907/09/21
Shares of Sigilon…
Shares of Sigilon Therapeutics are down 24.2% at $7.00 per share in pre-market trading following resumption of trade and after the FDA placed a clinical hold on the company's SIG-001 phase 1/2 study.
Sigilon Therapeutics Inc trading resumes 08:0007/0907/09/21
Sigilon Therapeutics to resume trading at 08:00EST 07:4007/0907/09/21
Sigilon Therapeutics announces clinical hold on SIG-001 Phase 1/2 study » 07:3107/0907/09/21
Sigilon Therapeutics reported that the U.S. Food and Drug Administration has notified the Company that its Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A, has been placed on clinical hold. The clinical hold was initiated following the Company's submission of a serious adverse event and temporary enrollment halt to the FDA and other regulatory agencies. To date, three patients have been dosed with SIG-001. The third patient, who received the highest dose of study drug, developed inhibitors to Factor VIII - a well-known complication of FVIII therapy. The patient is responding well to medical treatment and his condition continues to improve. Among other things, the FDA has requested additional information or data on factors potentially contributing to the development of inhibitors in this patient, such as family history and immune stimulation from a recent vaccination. All three patients enrolled in this study will continue to be followed per study protocol, while the company investigates the SAE. The status of the SAE investigation will continue to be reviewed by the Safety Review Committee for SIG-001 and Sigilon will provide additional data when available.
Sigilon Therapeutics Inc trading halted, news pending 07:2507/0907/09/21